A Study to Evaluate Molecular and Biochemical Testing for Suspected Hereditary Disorders

Overview

Información sobre este estudio

The objectives of this study are to perform molecular and/or biochemical testing in individuals with suspected hereditary disorders, and/or their family members, to further elucidate possible mechanisms of disease and/or inheritance, and/or to help yield a final laboratory diagnosis at the judgement of the original ordering healthcare provider. 

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

Both of the following criteria must be met for inclusion in this study OR Family members who are clinically unaffected or affected with the same suspected disorder as a patient with VUS:

  • Clinically suspected diagnosis of a genetic disorder.
  • All genetic testing performed to date has been equivocal.
  • Examples of “equivocal” results include:
    • A variant or variants of uncertain significance identified in a gene or genes of interest; borderline hypo- or hypermethylation on a previous targeted methylation assay such as methylation-sensitive MLPA; borderline droplet count or copy number detected by ddPCR or qPCR, respectively;
    • A single mutation identified in a gene of interest, such as via Sanger sequencing, next generation sequencing, or chromosomal microarray, associated with an autosomal recessive disorder in which two mutations must be present in order to be causative (i.e., no second mutation was identified); a pathogenic or likely pathogenic finding that is inconsistent with the current clinical phenotype of the patient  (i.e., the patient’s presentation is still unsolved) or inconsistent with the currently known mode of inheritance for a particular genetic disorder.

Exclusion Criteria:

  • Blood transfusion within the past 2 weeks.
  • Previous bone marrow transplant.
  • Chemotherapy or radiation therapy within the past 6 months.

Eligibility last updated 3/7/22. Questions regarding updates should be directed to the study team contact.

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Rochester, Minn.

Investigador principal de Mayo Clinic

Linda Hasadsri, M.D., Ph.D.

Abierto para la inscripción

Contact information:

Makala Amundson

(507) 266-0201

Amundson.Makala@mayo.edu

More information

Publicaciones

Publications are currently not available